Ole Hyldegaard

Prof. Dr. Ole Hyldegaard

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
IGINFECT study group
INFECT study group
MMMartin Bruun Madsen
Martin Bruun Madsen
SSSteinar Skrede
Steinar Skrede
APAnders Perner
Anders Perner
PAPer Arnell
Per Arnell
OHOle Hyldegaard
Ole Hyldegaard

7 July 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
NSNikolai Siemens
Nikolai Siemens
BCBhavya Chakrakodi
Bhavya Chakrakodi
SSSrikanth Mairpady Shambat
Srikanth Mairpady Shambat
MMMarina Morgan
Marina Morgan
HBHelena Bergsten
Helena Bergsten
ATAnna Norrby Teglund
Anna Norrby Teglund
Necrotizing fasciitis caused by group A streptococcus (GAS) is a life-threatening, rapidly progressing infection. At present, biofilm is not recognized as a potential problem in GAS necrotizing soft tissue infections (NSTI), as it is typically linked to chronic infections or associated with foreign devices. Here, we present a case of a previously healthy male presenting with NSTI caused by GAS. The infection persisted over 24 days, and the surgeon documented the presence of a “thick layer biofilm” in the fascia. Subsequent analysis of NSTI patient tissue biopsies prospectively included in a multicenter study revealed multiple areas of biofilm in 32% of the patients studied. Biopsies associated with biofilm formation were characterized by massive bacterial load, a pronounced inflammatory response, and clinical signs of more severe tissue involvement. In vitro infections of a human skin tissue model with GAS NSTI isolates also revealed multilayered fibrous biofilm structures, which were found to be under the control of the global Nra gene regulator. The finding of GAS biofilm formation in NSTIs emphasizes the urgent need for biofilm to be considered as a potential complicating microbiological feature of GAS NSTI and, consequently, emphasizes reconsideration of antibiotic treatment protocols.

31 January 2019 in Acta Oncologica
Verified
Journal Article
Closed access
GAGunn Ammitzbøll
Gunn Ammitzbøll
TKTrille Kristina Kjær
Trille Kristina Kjær
CJChristoffer Johansen
Christoffer Johansen
CLCharlotte Lanng
Charlotte Lanng
EAElisabeth Wreford Andersen
Elisabeth Wreford Andersen
SDSusanne Oksbjerg Dalton
Susanne Oksbjerg Dalton
Aims: To examine the effect of progressive resistance training (PRT) on health related quality of life and a predefined symptom cluster of pain–sleep–fatigue. Methods: This study was a planned secondary analysis of a randomized controlled trial examining the effect of PRT on prevention of arm lymphedema in a population of women between 18 and 75 years undergoing breast cancer surgery with axillary lymph node dissection. Participants were allocated by computer randomization to usual care control or a PRT intervention in a 1:1 ratio. The intervention, initiated in the third post-operative week, consisted of three times PRT per week, supervised in groups in the first 20 weeks, and self-administered in the following 30 weeks. Questionnaire assessments were made at baseline, 20 weeks and 12 months, with the European Organization for Research and Treatment in Cancer Core questionnaire (EORTC QLQ C30) and the Functional Assessment of Chronic Illness Therapy-(FACIT) fatigue questionnaire. The symptom cluster of pain–sleep–fatigue was measured with a constructed score adding EORTC C30 subscales of insomnia, pain, and fatigue. Data were treated as repeated measurements and analyzed with mixed models. Results: Among 158 recruited participants, we found a clinically relevant increased emotional functioning with nine points at both follow-ups (p = .02), and 16 and 11 points at 20 weeks and 12 months respectively (p = .04) in social functioning. Furthermore, in the subgroup of women with the symptom cluster pain–sleep–fatigue present at baseline, a significant effect was found for global health status (p = .01) and social functioning (p = .02). Conclusion: To our knowledge, this is the first study to report clinically relevant effects of PRT on social and emotional functioning in the first postoperative year after breast cancer surgery. Furthermore, a subgroup of women with the pain–sleep–fatigue symptom cluster had particular benefit from PRT on global health status and social functioning.

15 February 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
MHMarco Bo Hansen
Marco Bo Hansen
LRLars Simon Rasmussen
Lars Simon Rasmussen
PGPeter Garred
Peter Garred
DBDaniel Bidstrup
Daniel Bidstrup
MMMartin Bruun Madsen
Martin Bruun Madsen
OHOle Hyldegaard
Ole Hyldegaard
Background: New biomarkers are needed to assess the severity of necrotizing soft tissue infection (NSTI) at an early stage and to individualize treatment strategies. We assessed pentraxin-3 (PTX3) as a marker of disease severity and risk of death in patients with NSTI. Methods: We conducted a prospective, observational study in the intensive care unit at Copenhagen University Hospital, where treatment of NSTI is centralized at a national level. We compared PTX3, procalcitonin and C-reactive protein in septic shock versus nonshock patients and in amputated versus nonamputated patients using the Mann-Whitney U test. The prognostic value of the markers for 180-day mortality was assessed using Cox regression analyses. Results: Patients with NSTI (n = 135) were included over 25 months with up to 2.5-year follow-up; 71 % had septic shock, amputation was undertaken in 20 % and the 180-day mortality was 27 %. Baseline plasma PTX3 level was significantly higher in patients with septic shock (67.3 versus 24.6 ng/mL, p < 0.0001) and in patients who underwent amputation (118.6 versus 43.6 ng/mL, p = 0.019). No significant differences in baseline procalcitonin or C-reactive protein levels were found according to amputation (25.2 versus 7.0 μg/L, p = 0.060 and 202 versus 225 mg/L, p = 0.123), respectively. Baseline PTX3 level above the median was associated with death (p = 0.009, log-rank test) and the univariate Cox regression analysis revealed a significant association between PTX3 level upon admission and 180-day mortality (hazard ratio 2.60 (95 % confidence interval 1.28–5.29), p = 0.008). When adjusted for age, sex, chronic disease and Simplified Acute Physiology Score II, no significant association was found. Conclusions: High PTX3 level is associated with septic shock, amputation and risk of death in patients with NSTI, but it is not an independent predictor of 180-day mortality in this patient group. Trial registration: ClinicalTrials.gov Identifier: NCT02180906. Date of registration: June 29, 2014.

9 January 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
HBHelena Bergsten
Helena Bergsten
MMMartin Bruun Madsen
Martin Bruun Madsen
FBFrancois Bergey
Francois Bergey
OHOle Hyldegaard
Ole Hyldegaard
SSSteinar Skrede
Steinar Skrede
VSVítor Martins Dos Santos
Vítor Martins Dos Santos
Analyses of plasma collected pre- and postadministration of intravenous immunoglobulin (IVIG) from patients with group A Streptococcus necrotizing soft tissue infections demonstrated a negative correlation between IVIG dose and toxin-triggered T-cell proliferation (r = −.67, P < .0001). One 25-g IVIG dose was sufficient to yield plasma-neutralizing activity against streptococcal superantigens.Clinical Trials Registration. NCT 01790698 and NCT02111161.

15 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LMLaura M. Palma Medina
Laura M. Palma Medina
EREivind Rath
Eivind Rath
SJSanjeevan Jahagirdar
Sanjeevan Jahagirdar
TBTrond Bruun
Trond Bruun
MMMartin B. Madsen
Martin B. Madsen
ATAnna Norrby Teglund
Anna Norrby Teglund
BACKGROUND. Necrotizing soft-tissue infections (NSTIs) are rapidly progressing infections frequently complicated by septic shock and associated with high mortality. Early diagnosis is critical for patient outcome, but challenging due to vague initial symptoms. Here, we identified predictive biomarkers for NSTI clinical phenotypes and outcomes using a prospective multicenter NSTI patient cohort. METHODS. Luminex multiplex assays were used to assess 36 soluble factors in plasma from NSTI patients with positive microbiological cultures (n = 251 and n = 60 in the discovery and validation cohorts, respectively). Control groups for comparative analyses included surgical controls (n = 20), non-NSTI controls (i.e., suspected NSTI with no necrosis detected upon exploratory surgery, n = 20), and sepsis patients (n = 24). RESULTS. Thrombomodulin was identified as a unique biomarker for detection of NSTI (AUC, 0.95). A distinct profile discriminating mono- (type II) versus polymicrobial (type I) NSTI types was identified based on differential expression of IL-2, IL-10, IL-22, CXCL10, Fas-ligand, and MMP9 (AUC >0.7). While each NSTI type displayed a distinct array of biomarkers predicting septic shock, granulocyte CSF (G-CSF), S100A8, and IL-6 were shared by both types (AUC >0.78). Finally, differential connectivity analysis revealed distinctive networks associated with specific clinical phenotypes. CONCLUSIONS. This study identifies predictive biomarkers for NSTI clinical phenotypes of potential value for diagnostic, prognostic, and therapeutic approaches in NSTIs. TRIAL REGISTRATION. ClinicalTrials.gov NCT01790698. FUNDING. Center for Innovative Medicine (CIMED); Region Stockholm; Swedish Research Council; European Union; Vinnova; Innovation Fund Denmark; Research Council of Norway; Netherlands Organisation for Health Research and Development; DLR Federal Ministry of Education and Research; and Swedish Children’s Cancer Foundation.